Cargando…
Resolution of Coronavirus Disease 2019 Infection and Pulmonary Pathology With Nebulized DAS181: A Pilot Study
OBJECTIVES: Severe acute respiratory syndrome coronavirus 2 infections commonly lead to respiratory failure and potentially fatal systemic inflammation and organ failure. Nebulized DAS181, a host-directed biologics with sialidase activity, is an investigational drug with antiviral activities on para...
Autores principales: | Ho, Jennifer Hui-Chun, Zhao, Yang, Liu, Zhenlian, Zhou, Xiaoyang, Chen, Xiaobei, Xianyu, Yunyan, Lewis, Stanley, Fan, Liya, Tian, Yuan, Chang, Nancy, Gong, Zuojiong, Hu, Ke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587449/ https://www.ncbi.nlm.nih.gov/pubmed/33134951 http://dx.doi.org/10.1097/CCE.0000000000000263 |
Ejemplares similares
-
Critical patients with coronavirus disease 2019: Risk factors and outcome nomogram
por: Li, Lingzhi, et al.
Publicado: (2020) -
A Safety Evaluation of DAS181, a Sialidase Fusion Protein, in Rodents
por: Larson, Jeffrey L., et al.
Publicado: (2011) -
Successful Treatment of Parainfluenza Virus Respiratory Tract Infection With DAS181 in 4 Immunocompromised Children
por: Waghmare, Alpana, et al.
Publicado: (2015) -
Nebulized Nitroglycerin for Coronavirus Disease 2019–Associated Acute Respiratory Distress Syndrome: A Case Report
por: Daxon, Benjamin T., et al.
Publicado: (2021) -
DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study
por: Chemaly, Roy F, et al.
Publicado: (2021)